"Phenytoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
Descriptor ID |
D010672
|
MeSH Number(s) |
D03.383.129.308.432.555.730
|
Concept/Terms |
Phenytoin- Phenytoin
- 5,5-Diphenylhydantoin
- Fenitoin
- 5,5-diphenylimidazolidine-2,4-dione
- Diphenylhydantoin
Phenytoin Sodium- Phenytoin Sodium
- Sodium Diphenylhydantoinate
- Diphenylhydantoinate, Sodium
|
Below are MeSH descriptors whose meaning is more general than "Phenytoin".
Below are MeSH descriptors whose meaning is more specific than "Phenytoin".
This graph shows the total number of publications written about "Phenytoin" by people in this website by year, and whether "Phenytoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phenytoin" by people in Profiles.
-
Mintzer S, Skidmore CT, Sperling MR. B-vitamin deficiency in patients treated with antiepileptic drugs. Epilepsy Behav. 2012 Jul; 24(3):341-4.
-
Mintzer S, Skidmore CT, Rankin SJ, Chervoneva I, Pequinot E, Capuzzi DM, Sperling MR. Conversion from enzyme-inducing antiepileptic drugs to topiramate: effects on lipids and C-reactive protein. Epilepsy Res. 2012 Jan; 98(1):88-93.
-
Zangaladze A, Asadi-Pooya AA, Ashkenazi A, Sperling MR. Sporadic hemiplegic migraine and epilepsy associated with CACNA1A gene mutation. Epilepsy Behav. 2010 Feb; 17(2):293-5.
-
Mintzer S, Mattson RT. Should enzyme-inducing antiepileptic drugs be considered first-line agents? Epilepsia. 2009 Sep; 50 Suppl 8:42-50.
-
Anderson JD, Hansen TP, Lenkowski PW, Walls AM, Choudhury IM, Schenck HA, Friehling M, Höll GM, Patel MK, Sikes RA, Brown ML. Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. Mol Cancer Ther. 2003 Nov; 2(11):1149-54.
-
Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit. 2002 Jun; 24(3):379-85.